• Abbott Laboratories has announced plans to separate its global Nutrition division into an independent, publicly traded company with about US$8.5b in annual sales, supported by 16,000 employees and 14 manufacturing sites worldwide.
• The Nutrition spin off concentrates brands like Ensure, PediaSure, Glucerna and Similac in a focused entity that can align product launches and capital spending directly with healthy nutrition trends and category specific regulatory requirements.
• This development raises questions about how Abbott Laboratories' investment narrative could shift as the Nutrition spin off reshapes capital allocation and segment focus.

Spot 34 healthcare AI stocks that, like Abbott Laboratories, are trying to turn cutting edge diagnostics and medical technology into durable healthcare cash flows.

Abbott Laboratories Investment Narrative Recap

To stay invested in Abbott Laboratories, investors need to believe the portfolio can convert its medical technology pipeline into steadier earnings, even as Nutrition separates. The short-term story now hinges on executing through mixed Q3 2026 results, with higher sales but lower net income and diluted EPS from continuing operations at US$0.53 for the quarter and US$1.67 for the nine-month period.

The biggest near-term swing factor is how margin pressure from legal costs, capital spending and diabetes pricing develops relative to growth drivers in diagnostics, Libre and electrophysiology. Legal and regulatory exposure in Nutrition, together with a high debt load and a dividend that is not well covered by earnings, remain key operational risks.

The new Beta CORRECT data around Abbott Laboratories' whole genome sequencing based Oncodetect MRD test is a clear link between the spin-off story and the diagnostics catalyst. Management is focusing on cancer testing, where higher margin revenue can help offset pressure in other units, and this colorectal study provides additional clinical support for that part of the portfolio.

Oncodetect tracked up to 5,000 tumor-specific DNA variants and reached 72.2% sensitivity for recurrence within two years on a single post-surgery blood draw, compared with 42.2% for the WES version. Detectable ctDNA after surgery was the strongest predictor of recurrence in the study, which strengthens the commercial case for Abbott's cancer diagnostics strategy while also highlighting execution risk around reimbursement, adoption and ongoing trial investment.

Abbott Laboratories' current analyst narrative points to US$60.0b in revenue and US$9.6b in earnings by 2029. This lines up with an assumed 8.8% yearly revenue growth rate and implies an earnings increase of about US$4.2b from US$5.4b today.

Uncover why Abbott Laboratories' fair value indicates a 16% potential upside to its current price that could close sooner than many investors expect.

Exploring Other Perspectives

The Simply Wall St Community currently has four fair value views on Abbott Laboratories, stretching from about US$118.64 to roughly US$149.41 per share. Those private investors are not aligned, and neither should you assume they will be. If you then layer on legal exposure in Nutrition and fresh Oncodetect MRD data, you get very different stories for earnings resilience. Use that spread as a prompt to compare several viewpoints before deciding how this evolving healthcare mix fits your own portfolio goals.

Explore 3 other Abbott Laboratories fair value estimates, including one that suggests as much as 44% potential increase from the current price!

Form Your Own Verdict

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Abbott Laboratories research is our analysis highlighting 2 key rewards and 3 important warning signs that could impact your investment decision.
• See our latest analysis for Abbott Laboratories. The report includes a comprehensive fundamental analysis summarized in a single visual, the Snowflake, making it easy to evaluate Abbott Laboratories' overall financial health at a glance.

Looking for more ideas beyond Abbott Laboratories?

If the Abbott Laboratories story has you rethinking how healthcare fits into your portfolio, use the Simply Wall St Screener to line up other potential candidates with fundamentals that match your own risk and income preferences.

• For investors hunting for quality at a sensible entry point, scan through a focused 27 high quality undervalued stocks that already clear basic balance sheet and earnings checks.
• If capital preservation matters as much as returns, filter for sturdier businesses using a 30 resilient stocks with low risk scores that aims to highlight companies with fewer financial red flags.
• When you want strong finances to underpin long term compounding, start with a list of solid balance sheet and fundamentals (25 results) so you are only comparing companies with cleaner leverage and liquidity profiles.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.